Glaxosmithkline | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Amgen USD 23.1B 2.79B 2024-12
AstraZeneca USD 27.87B 1.94B 2024-12
Aurora Cannabis CAD 149.81M 40.71M 2024-12
Bausch Health Companies USD 4.51B 137M 2024-09
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Canopy Growth CAD 97.02M 184.27M 2024-12
Corcept Therapeutics USD 140.77M 14.56M 2024-12
Drreddys Laboratories INR 131.95B 2.65B 2024-12
Eli Lilly USD 28.38B 3.7B 2024-12
GlaxoSmithKline GBP 21.7B 238M 2024-12
Glaxosmithkline GBP 21.7B 238M 2024-12
Indivior 962M 50M 2024-09
J&J USD 50.32B 1.44B 2024-12
Merck USD 28.42B 1.17B 2024-12
Novartis USD 28.69B 560M 2024-12
Pacira USD 309.92M 3.52M 2024-12
Perrigo USD 1.04B 406.3M 2024-12
Pfizer USD 43B 216M 2024-12
Prestige Brands USD 102.54M 4.36M 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 30.03B 5.82B 2024-06
Supernus Pharmaceuticals USD 292.4M 889K 2024-12
Takeda JPY 2.1T 289.27B 2024-12
Teva Pharmaceutical Industries USD 12.8B 1B 2024-12
Zoetis USD 3.41B 1.71B 2024-12



Glaxosmithkline Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.